The tetracyclines have been widely used during in last four decades, due to their broad-spectrum of antimicrobial activity against Gram-positive and Gramnegative aerobic bacteria, including many intracellular pathogens and anaerobic organisms [1, 2] . However, indications for the use of tetracyclines have been limited to specific clinical indications, due to the emergence of resistant strains in frequently isolated species, such as Staphylococcus aureus, Enterococcus spp., Streptococcus pneumoniae, and Neisseria gonorrhoeae [1] [2] [3] [4] .
Tigecycline, former GAR-936, is the first representative of a new class of antimicrobial agents known as glycylcyclines. This compound is a semisynthetic 9-t-butylglycylamido derivative of the minocycline molecule [5] . Although tigecycline acts on the bacterial ribosome by binding sites similar to those of tetracycline, the radical added to position 9 of the tigecycline molecule has provided additional steric hindrance features that result in a greater spectrum of activity [6] . Thus, tigecycline has documented activity against tetracycline-resistant (tet-R) Gram-positive and Gram-negative pathogens, refractory to both efflux and ribosomal protection mechanisms [7] .
Our main objective was to evaluate the in vitro activity of tigecycline in comparison to tetracycline and other antimicrobial agents against clinical bacterial isolates recently collected from Latin American medical centers. (8 strains) . Only a single isolate per patient was evaluated. The isolates were identified to the species level by the participating medical center, and sent to the coordinating laboratory for identification confirmation and reference susceptibility testing.
Material and Methods

Organisms
Medical centers
Clinical isolates of facultatively aerobic bacteria were collected in 11 Latin American laboratories distributed throughout 10 cities (six countries): São Paulo, Florianópolis, Porto Alegre and Brasília (only 2002), Brazil; Buenos Aires and San Isidro, Argentina; Santiago (two centers), Chile; Medellin, Colombia (only 2000); Caracas, Venezuela; and Mexico City, Mexico. The selection of participating centers was based on the principle that they should be sentinels in their respective geographic region. The participating medical centers were directed by a protocol to collect isolates from consecutive patients from specific sites of infections, including bloodstream infections, community-acquired respiratory infections, pneumonia in hospitalized patients, and skin and soft tissue infections.
Susceptibility testing
Antimicrobial susceptibility testing was performed using broth microdilution methods, as described by the Clinical Laboratory Standard Institute (CLSI, formerly NCCLS) [8] . Antimicrobial agents were obtained from their respective manufacturers as laboratory grade powder. Minimal inhibitory concentrations (MICs) results were interpreted according to NCCLS breakpoints [9] . A tigecycline susceptible breakpoint of <4 µg/mL for staphylococci and enterococci, and ≤ 2 µg/mL for other pathogens were used for comparative purposes only. Quality control measures were utilized by testing S. pneumoniae ATCC 49619, S. aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922, and Pseudomonas aeruginosa ATCC 27853.
Results
The largest number of isolates was collected from the Brazilian medical centers (573 isolates, 43.2%), followed by the Chilean (377 isolates, 28.4%) and Argentinean (264 isolates, 19.9%) medical centers. These three countries contributed with >90% of isolates ( Table 1) . Species tested in rank order of frequency were as follows: S. aureus (42.9% oxacillin-resistant); S. pneumoniae (27.1% penicillin-non-susceptible), CoNS (79.3% oxacillin-resistant), H. influenzae (17.8% β-lactamase-producers), Enterococcus spp. (10.3% vancomycin-resistant), M. catarrhalis (92.6% β-lactamase-producers), β-haemolytic streptococci (34.6% erythromycin-non-susceptible), viridans group streptococci (30.8% penicillin-non-susceptible), and Neisseria meningitides.
The antimicrobial activity of tigecycline was compared to selected antimicrobial agents (Table 2 ). Tigecycline was highly active against both oxacillin-resistant andsusceptible S. aureus (MIC 50 , 0.25 µg/mL and MIC 90 , 0.5 µg/mL for both groups). More than 99% of the strains were inhibited at <0.5 µg/mL of tigecycline. Similarly to S. aureus, both oxacillin-resistant and -susceptible coagulase-negative staphylococci were very susceptible to tigeclycline (MIC 50 , 0.25 µg/mL and MIC 90 , 0.5 µg/ mL for both). Vancomycin and linezolid were the only antimicrobial agents active against all staphylococcal strains at the susceptible breakpoint. Tigecycline (MIC 50 , 0.25 µg/mL) was at least four-fold more potent than vancomycin (MIC 50 , 1 µg/mL) or linezolid (MIC 50 , 1-2 µg/mL) against oxacillin-resistant staphylococci. Tigecycline was also highly active against tetracyclineresistant staphylococci. Co-resistance among tetracycline, erythromycin, and fluoroquinolones was noticed within the subsets of oxacillin-resistant staphylococci and did not affect tigecycline in vitro activity against staphylococci.
Although tigecycline and linezolid inhibited 100% of the Enterococcus spp. strains tested, tigecycline (MIC 50 , 0.25 µg/mL) was eight-fold more potent than linezolid (MIC 50 , 2 µg/mL). The vast majority of Enterococcus spp. were susceptible to ampicillin (MIC 50 , ≤ 1 µg/mL; 88.8% susceptible) and resistant to quinupristin/dalfopristin (MIC 50 , 8 µg/mL; 13.8% susceptible), reflecting the preponderance of E. faecalis in the collection. Tigecycline showed excellent potency against both vancomycin-and tetracyclineresistant Enterococcus spp. Against S. pneumoniae, tigecycline, gatifloxacin, quinupristin/dalfopristin, vancomycin, teicoplanin, and linezolid showed a susceptibility rate of 100.0%. Four S. pneumoniae isolates were not susceptible to ceftriaxone when non-meningitis breakpoints were applied. Tigecycline (MIC 50 , 0.12 µg/mL) was as potent as teicoplanin (MIC 50 , 0.12 µg/mL) and two-fold more potent than ceftriaxone (MIC 50 , 0.25 µg/mL), gatifloxacin (MIC 50 , 0.25 µg/mL), and vancomycin (MIC 50 , 0.25 µg/mL) against S. pneumoniae. Tigecycline was also highly active against S. pneumoniae, including isolates resistant to penicillin and/or tetracycline and/or erythromycin.
Tigecycline demonstrated excellent activity against viridans group streptococci (MIC 50/90 , ≤ 0.12/0.25 µg/ mL) and β-haemolytic streptococci (MIC 50/90 , ≤ 0.12 µg/mL), whereas the corresponding MIC 90 values for tetracycline were > 8 µg/mL. Tigecycline, vancomycin, teicoplanin, and linezolid (100.0% susceptible) exhibited excellent coverage against these pathogens. No cross-resistance between tigecycline and any of the antimicrobial agents tested was observed among streptococcal isolates. Percentage of susceptibility calculated using the NCCLS breakpoints [9] . c A susceptible breakpoint of ≤ 4 µg/mL was used for comparative purposes only. Nearly 18.0% and 93.0% of the H. influenzae and M. catarrhalis strains produced β-lactamase, respectively. Haemophilus influenzae (MIC 50/90 , 0.25 µg/mL) and M. catarrhalis (MIC 50/90 , ≤ 0.12/ 0.5 µg/mL) isolates were very susceptible to tigecycline (100.0% susceptible), including β-lactamase producing isolates. Only eight N. meningitidis isolates were tested. Seven of them were collected from a Chilean medical center. All of the N. meningitidis showed tigecycline MIC at concentrations ≤ 0.12 µg/mL. The tigecycline MIC distribution among 1,326 pathogens tested is shown in Table 3 . The tigecycline MICs distributions were not influenced by co-phenotypes of resistance, such as oxacillin-resistance among staphylococci, penicillin-resistance among S. pneumoniae or glycopeptide resistance among Enterococcus spp.
The vast majority of isolates tested (1320 of 1326 or 99.5%) were inhibited at a concentration of ≤ 1 µg/mL of tigecycline.
Discussion
Tigecycline, a novel glycylcycline antibiotic, exhibits strong activity against Gram-positive, Gram-negative, aerobic, anaerobic, and atypical bacterial species, including many resistant pathogens, i.e., vancomycinresistant enterococci, methicillin-resistant S. aureus and penicillin-resistant S. pneumoniae [10] [11] [12] [13] . In addition, tigecycline has shown excellent activity against most Gram-negative pathogens, including Enterobacteriaceae, Acinetobacter spp., Stenotrophomonas maltophilia [10, 11] , Haemophilus influenzae, and Neisseria spp. [14] . Tigecycline's expanded broad-spectrum activity is further evidenced by its activity against Legionella pneumophila [15] , Chlamydia [16] , rapidly growing nontuberculosis mycobacteria [17] and anaerobes [18] . On the other hand, tigecycline has demonstrated limited activity against P. aeruginosa and Proteae isolates [5, 10, 11] .
Tigecycline Antimicrobial Activity in Latin America The results of two randomized trials assessing the clinical efficacy of tigecycline were recently released [19] . The studies evaluated tigecycline versus vancomycin plus aztreonam to treat complicated skin and skin structure infections (cSSSI), and tigecycline versus imipenem plus cilastatin to treat complicated intrabdominal infections (cIAI). In the first trial, 274 patients received tigecycline and 269 received vancomycin plus aztreonam. The clinical cure rate of cSSSI between the two groups was not statistically different (84.3% versus 86.9%, respectively). The cIAI trial comprised 404 and 413 patients treated with tigecycline and imipenem plus cilastatin, respectively. Clinical cure was again not statistically distinct (86.6% of the tigecycline group and in 84.4% of those on combination therapy). In both trials, the most frequently reported adverse events for patients on tigecycline were nausea and vomiting [19] .
Our results agree with previous in vitro studies [5, [10] [11] [12] [13] [14] and emphasize that tigecycline has excellent activity and spectrum against Gram-positive bacteria, including multi-drug resistant strains, and bacterial pathogens causing community-acquired respiratory tract infections isolated from patients hospitalized in Latin American medical centers. These results, associated with the tigecycline clinical efficacy data already published, suggest that tigecycline may have an important role in the treatment of severely ill patients, especially in an environment with high antimicrobial resistance levels such as the Latin American region.
